Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
复制标题
DOI：
10.2147/ott.s93238
复制
发表时间：
2015
影响因子：
4
通讯作者：
Hu CS
中科院分区：
文献类型：
--
作者：
Zhai RP;Ying HM;Kong FF;Du CR;Huang S;Zhou JJ;Hu CS
评价尼妥珠单抗联合调强放疗（IMRT）初治局部晚期鼻咽癌的疗效和安全性。2009年12月至2013年12月期间，38例新诊断的III-IV期鼻咽癌患者接受了IMRT和尼妥珠单抗伴随治疗。疾病分布为III期20例（52.6%），IV A期9例（23.7%），IV B期9例（23.7%）。所有患者均接受至少两个周期的顺铂为基础的新辅助化疗，随后接受尼妥珠单抗200 mg/周，同时接受调强放疗。根据放射治疗肿瘤学组的急性和晚期放射死亡评分标准对急性和晚期放射相关毒性进行分级。中位随访时间为39.7个月（范围13.3-66.5个月），估计3年局部无复发生存率、区域无复发生存率、无远处转移生存率、无进展失败生存率和总生存率分别为92.8%、92.9%、89.5%、78.7%和87.5%。尼妥珠单抗添加的中位周期为6周。3级放射性粘膜炎占治疗人群的36.8%。未观察到皮疹和输液反应，与西妥昔单抗治疗患者报告的情况明显不同。尼妥珠单抗加调强放疗在局部控制和生存方面显示出有希望的结果，而不会增加患者放射相关毒性的发生率。
To evaluate the efficacy and safety of using nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) in the primary treatment of locoregionally advanced nasopharyngeal carcinoma. Between December 2009 and December 2013, 38 newly diagnosed patients with stage III–IV nasopharyngeal carcinoma were treated with IMRT and nimotuzumab concomitantly. The distribution of disease was stage III in 20 (52.6%), stage IV A in 9 (23.7%), and stage IV B in 9 (23.7%). All the patients received at least two cycles of cisplatin-based neoadjuvant chemotherapy followed by nimotuzumab 200 mg/week concurrently with IMRT. Acute and late radiation-related toxicities were graded according to the Acute and Late Radiation Morbidity Scoring Criteria of Radiation Therapy Oncology Group. With a median follow-up of 39.7 months (range, 13.3–66.5 months), the estimated 3-year local recurrence-free survival, regional recurrence-free survival, distant metastasis-free survival, progression failure-free survival, and overall survival rates were 92.8%, 92.9%, 89.5%, 78.7%, and 87.5%, respectively. The median cycle for nimotuzumab addition was 6 weeks. Grade 3 radiation-induced mucositis accounted for 36.8% of treated people. No skin rash and infusion reaction were observed, distinctly from what is reported in cetuximab-treated patients. Nimotuzumab plus IMRT showed promising outcomes in terms of locoregional control and survival, without increasing the incidence of radiation-related toxicities for patients.